Novo Integrated Sciences (NVOS) AI Stock Analysis

• Market Cap: $23.68K
• Dividend Yield: N/A
• Average Volume (3M): 49.12K
• Price to Earnings (P/E): ―
• Beta (1Y): -4.05
• Revenue Growth: 5.75%
• EPS Growth: 55.68%
• Country: US
• Employees: 115
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 19,730,247
• 10 Day Avg. Volume: 41,823
• 30 Day Avg. Volume: 49,120
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Novo Integrated Sciences faces significant operational and financial challenges, with negative profit margins and cash flows. The technical indicators reflect a bearish trend, and the negative P/E ratio highlights valuation concerns. Strategic improvements in cost management and operational efficiency are needed to improve financial health and investor confidence.

Novo Integrated Sciences Business Overview & Revenue Model

Company Description

Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services. It operates through two segments, Healthcare Services, and Product Manufacturing and Development. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations. In addition, the company offers eldercare physiotherapy services, such as long-term care homes, retirement homes, community based home care physiotherapy, community based group exercise classes and fall prevention programs, and community-based outpatient clinics; and elderly occupational therapy services for retirement home and community, and long-term care sectors. Further, it offers medical technology services, such as telemedicine and remote patient monitoring; and develops and distributes personalized health and wellness product solutions. The company operates 16 owned clinics. The company was incorporated in 2000 and is based in Bellevue, Washington. Novo Integrated Sciences, Inc. operates as a subsidiary of ALMC-ASAP Holdings, Inc.

How the Company Makes Money

Novo Integrated Sciences primarily makes money through its comprehensive healthcare services and technology solutions offered to both individual patients and healthcare providers. Revenue streams include direct patient services, technology licensing, and partnerships with healthcare institutions. The company also engages in strategic collaborations to expand its service offerings and enhance its technological capabilities, contributing to its overall earnings.

Novo Integrated Sciences Financial Statement Overview

Summary

Novo Integrated Sciences is experiencing revenue growth, but profitability and cash flow challenges persist. The company struggles with negative margins and cash flows, indicating potential operational inefficiencies and financial sustainability issues. While leverage is controlled, declining equity ratios and negative ROE highlight financial instability. Strategic improvements in cost management and operational efficiency are crucial for future financial health.

Income Statement

Novo Integrated Sciences has shown consistent revenue growth over the years, with revenue increasing from $7.86M in 2020 to $13.29M in 2024. However, the company faces challenges with negative EBIT and net income, resulting in negative profit margins. In 2024, the EBIT margin was -75.8% and the net profit margin was -121.3%, indicating significant operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's debt-to-equity ratio improved slightly from 0.18 in 2020 to 0.32 in 2024, but remains relatively low, indicating conservative leverage. However, the equity ratio has decreased from 83.7% in 2020 to 46.3% in 2024, reflecting a declining proportion of equity in the asset structure. Return on equity is negative, primarily due to negative net income, which is a concern for profitability.

Cash Flow

Free cash flow has been consistently negative, with a significant decline in free cash flow growth from 2020 to 2024. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient operational cash flow to cover its losses. This raises concerns about the sustainability of operations without additional financing.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
13.52M	13.29M	12.57M	11.74M	9.31M	7.86M
	Gross Profit
5.09M	5.74M	4.95M	4.80M	3.82M	3.06M
	EBIT
-10.47M	-10.08M	-8.55M	-25.03M	-4.37M	-4.26M
	EBITDA
-16.02M	-10.08M	-5.85M	-22.48M	-2.58M	-2.78M
	Net Income Common Stockholders
-24.33M	-16.13M	-13.21M	-32.85M	-4.46M	-4.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.37M	844.58K	416.32K	2.18M	8.29M	2.07M
	Total Assets
29.08M	32.14M	35.56M	40.87M	61.96M	35.39M
	Total Debt
1.60M	4.71M	4.47M	13.00M	13.71M	4.39M
	Net Debt
-778.30K	3.87M	4.06M	10.82M	5.42M	2.33M
	Total Liabilities
4.25M	17.53M	11.06M	18.83M	18.15M	5.82M
	Stockholders Equity
24.87M	14.89M	24.82M	22.31M	43.86M	29.62M
Cash Flow		Free Cash Flow
-4.79M	-2.29M	-2.29M	-6.07M	-1.28M	-453.80K
	Operating Cash Flow
-4.75M	-2.24M	-2.24M	-5.88M	-1.02M	-441.69K
	Investing Cash Flow
-30.35K	-49.22K	-49.22K	163.46K	3.00M	657.13K
	Financing Cash Flow
5.59M	763.86K	763.86K	-427.12K	4.32M	-271.69K

Novo Integrated Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVOS, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.43 is Neutral, neither overbought nor oversold. The STOCH value of -1.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVOS.

Novo Integrated Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMS	55 Neutral	$18.06M	8.40	9.23%	―	32.90%	262.22%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.50%
CCEL	51 Neutral	$40.77M	403.60	93.38%	9.91%	2.33%	―
SYRA	42 Neutral	$1.44M	―	-94.29%	―	33.04%	39.30%
NVOS	34 Underperform	$23.68K	―	-81.43%	―	5.75%	55.68%
CCM	33 Underperform	$32.65M	―	14.03%	―	-29.82%	-2.57%
MODV	33 Underperform	$16.79M	―	-951.52%	―	-0.70%	-2.38%

Novo Integrated Sciences Corporate Events

Novo Integrated Sciences CEO Transition by May 31, 2025

On April 30, 2025, Novo Integrated Sciences announced that Robert Mattacchione’s resignation as CEO, initially set for February 5, 2025, has been extended multiple times to allow for a smooth transition, with the latest effective date no later than May 31, 2025. Despite stepping down as CEO, Mr. Mattacchione will continue as Chairman of the Board and Chairman of Novo Healthnet Limited. Additionally, Michael Pope resigned from the Board effective May 1, 2025, with both resignations not due to any disagreements with the company.

Spark’s Take on NVOS Stock

According to Spark, TipRanks’ AI Analyst, NVOS is a Underperform.

Novo Integrated Sciences faces significant operational and financial challenges, with negative profit margins and cash flows. The technical indicators reflect a bearish trend, and the negative P/E ratio highlights valuation concerns. Strategic improvements in cost management and operational efficiency are needed to improve financial health and investor confidence.

To see Spark’s full report on NVOS stock, click here.

Novo Integrated Sciences CEO Resignation Announcement

Robert Mattacchione, the CEO of Novo Integrated Sciences, Inc., announced his resignation effective February 5, 2025, which was later extended multiple times to April 30, 2025, to ensure a smooth transition. Despite stepping down as CEO, Mattacchione will remain as Chairman of the Board and Chairman of Novo Healthnet Limited, with his resignation not stemming from any disagreements with the company.

Novo Integrated Sciences CEO Resignation Announcement

Novo Integrated Sciences announced the resignation of Robert Mattacchione as CEO, effective no later than March 31, 2025, to ensure a smooth transition. Despite stepping down as CEO, Mattacchione will remain involved as Chairman of the Board and Chairman of Novo Healthnet Limited, with his resignation not stemming from any disagreements with the company.